Denali Therapeutics (NASDAQ:DNLI) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft

Equities research analysts at Deutsche Bank Aktiengesellschaft started coverage on shares of Denali Therapeutics (NASDAQ:DNLI - Get Free Report) in a research note issued on Tuesday, Marketbeat.com reports. The brokerage set a "buy" rating and a $31.00 price target on the stock. Deutsche Bank Aktiengesellschaft's price objective suggests a potential upside of 44.15% from the stock's previous close.

A number of other research analysts also recently issued reports on the company. William Blair reissued an "outperform" rating on shares of Denali Therapeutics in a report on Wednesday, January 15th. Robert W. Baird began coverage on Denali Therapeutics in a report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price target for the company. Jefferies Financial Group boosted their price target on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a report on Friday, November 1st. HC Wainwright decreased their price target on Denali Therapeutics from $90.00 to $87.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Finally, Baird R W upgraded Denali Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 7th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $37.42.

Denali Therapeutics Stock Up 0.9 %

Shares of Denali Therapeutics stock traded up $0.20 on Tuesday, reaching $21.51. 332,924 shares of the stock were exchanged, compared to its average volume of 970,632. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $33.33. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -7.79 and a beta of 1.43. The business has a 50 day moving average price of $21.98 and a two-hundred day moving average price of $24.76.

Insider Buying and Selling

In other Denali Therapeutics news, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the transaction, the director now directly owns 107,976 shares in the company, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the completion of the transaction, the chief executive officer now owns 260,721 shares in the company, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,940 shares of company stock valued at $973,442. Corporate insiders own 7.90% of the company's stock.

Hedge Funds Weigh In On Denali Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. MONECO Advisors LLC increased its stake in Denali Therapeutics by 4.6% in the third quarter. MONECO Advisors LLC now owns 9,100 shares of the company's stock valued at $265,000 after purchasing an additional 400 shares during the last quarter. Rhumbline Advisers increased its stake in Denali Therapeutics by 0.3% in the fourth quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock valued at $3,880,000 after purchasing an additional 497 shares during the last quarter. Assetmark Inc. increased its stake in Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after purchasing an additional 580 shares during the last quarter. CWM LLC increased its stake in Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company's stock valued at $63,000 after purchasing an additional 654 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after acquiring an additional 885 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.